Brief: Kezar Life Sciences Q3 Operating Expenses USD 21.948 Million
Nov 12 (Reuters) - Kezar Life Sciences Q3 operating income USD -21.948 million. * Q3 net income USD -20.313 million vs. IBES estimate USD -22.6 million
Recent news on Kezar Life Sciences
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM